drugset / Trial / NCT02659501

Liposomal Bupivacaine in Implant Based Breast Reconstruction

NCT02659501

Terminated 24 enrolled Loma Linda University
RandomizedParallel-groupSingle-blindTreatment

Summary

Objectives: 1. To evaluate the effect of liposomal bupivacaine on postoperative pain levels. 2. To evaluate the effect of liposomal bupivacaine on postoperative opioid consumption and opioid related adverse events. 3. To evaluate the effect of liposomal bupivacaine on length of hospital stay. 4. To evaluate the effect of liposomal bupivacaine on patient satisfaction with postoperative pain control. 5. To evaluate the effect of liposomal bupivacaine on overall patient satisfaction.

Timeline

Start
2015-07
Primary completion
2016-09
Completion
2017-07

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 50 mg Other
Comparator Bupivacaine Other / unclassified 133 mg Other
Background Diazepam Small molecule Oral
Background Hydrocodone/acetaminophen Unknown Oral
Background Morphine Other / unclassified Intravenous

Indications